Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Hannah Willis, Joshua Horns, Kelsey Baron, Allison Bock, Lindsey Fitzgerald, Narendranath Epperla, Harsh Shah, Boyu Hu, Deborah Stephens, Adam Kittai, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6316.

https://doi.org/10.1182/blood-2025-6316

Published: 2025

Journal Articles

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Aseel Alsouqi, Ying Huang, Lindsey Rike, Lillian Dweik, Swetha Hinton, Mollie Moran, Mark Reid, Corinne Hoffman, Cara Grantier, Margaret Lucas, Amneet Bajwa, Seema Bhat, Michael Grever, Kerry Rogers, Harsh Shah, Jennifer Woyach, Adam Kittai

Blood (2025) 146 (Supplement 1): 1953.

https://doi.org/10.1182/blood-2025-1953

Published: 2025

Journal Articles

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Blood (2025) 146 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2025-3622

Published: 2025

Journal Articles

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

Narendranath Epperla, Allison Bock, Boyu Hu, Yizhe Xu, Lindsey Fitzgerald, Daniel Ermann, Harsh Shah, Kelsey Baron, Nancy Bartlett

Blood (2025) 146 (Supplement 1): 3616.

https://doi.org/10.1182/blood-2025-3616

Published: 2025

Journal Articles

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Kelsey Baron, Charlotte Wagner, Lindsey Fitzgerald, Amber Jacoway, Ausha Marden, Daniel Ermann, Boyu Hu, Harsh Shah, Narendranath Epperla, Allison Bock

Blood (2025) 146 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2025-4485

Published: 2025

Journal Articles

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Narendranath Epperla, Allison Bock, Yizhe Xu, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Kelsey Baron, Daniel Ermann, Joe Mendez, Lindsay Burt, Donald Cannon, Amit Maity, Joshua Palmer, Iyad Alnahhas, Thomas Ollila

Blood (2025) 146 (Supplement 1): 8241.

https://doi.org/10.1182/blood-2025-8241

Published: 2025

Journal Articles

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)

Narendranath Epperla, Yizhe Xu, Allison Bock, Kelsey Baron, Lindsey Fitzgerald, Harsh Shah, Daniel Ermann, Lalit Sehgal, Lapo Alinari, Boyu Hu

Blood (2025) 146 (Supplement 1): 8235.

https://doi.org/10.1182/blood-2025-8235

Published: 2025

Journal Articles

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

Daniel A. Ermann, Victoria A. Vardell, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Boyu Hu

Blood (2023) 142 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2023-190383

Published: 2023

Journal Articles

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Victoria A. Vardell, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2023-190719

Published: 2023

Journal Articles

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

Blood (2023) 142 (Supplement 1): 4436.

https://doi.org/10.1182/blood-2023-173470

Published: 2023

Journal Articles

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Robert Stuver, Esther Drill, Nivetha Ganesan, Kelsey Baron, Ellie Casper, Tiffany Chang, Sanjal H. Desai, Ayo S Falade, Natasha Galasso, Alex F. Herrera, Matthew G. Mei, Reid W. Merryman, Ivana Micallef, Harsh Shah, Alison Moskowitz

Blood (2023) 142 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2023-182143

Published: 2023

Journal Articles

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Blood (2023) 142 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2023-182318

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Blood (2023) 142 (Supplement 1): 611.

https://doi.org/10.1182/blood-2023-172574

Published: 2023

Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Blood (2023) 142 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2023-188545

Published: 2023

Journal Articles

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Blood (2023) 142 (Supplement 1): 182.

https://doi.org/10.1182/blood-2023-179573

Published: 2023

Journal Articles

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Zach Rubnitz, Victoria A. Vardell, Lindsey Fitzgerald, Allison M. Bock, Harsh Shah, Boyu Hu, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 6169.

https://doi.org/10.1182/blood-2023-189285

Published: 2023

Journal Articles

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Greg Kirkpatrick, Jeffrey M. Switchenko, Melissa Kives, Katelin Baird, Kami J. Maddocks, Jason T. Romancik, Deborah M. Stephens, Harsh Shah, Javier Pinilla-Ibarz, Julio C Chavez, Matthew Matasar, Craig A. Portell, Michelle Churchman, Jonathon B. Cohen, Umar Farooq, Brian K. Link

Blood (2023) 142 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2023-187198

Published: 2023

Journal Articles

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Victoria A. Vardell, Daniel A. Ermann, Harsh Shah, Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 1085–1086.

https://doi.org/10.1182/blood-2022-169918

Published: 2022

Journal Articles

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Daniel A. Ermann, Victoria A. Vardell, Manasa Velagapudi, Greer Burkholder, Lindsey A. Fitzgerald, Mayur Narkhede, Harsh Shah, Lauren Shea, Adam Spivak, Deborah M. Stephens, Boyu Hu, Gaurav Goyal

Blood (2022) 140 (Supplement 1): 1076–1078.

https://doi.org/10.1182/blood-2022-169930

Published: 2022

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Impact of Peri-Transplant Radiation on Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only